Quantum BioPharma (NASDAQ: QNTM) was featured in a Men’s Fitness article by Lakshan Weeraratne that examined clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article, reported by NEWMEDIAWIRE, brings public attention to a small company-sponsored study and its mixed findings, a development that matters for investors and consumers navigating the growing market for alcohol recovery products.
The study was a placebo-controlled trial involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness, and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo. Those results, while notable, come from a small sample and require cautious interpretation.
The Men’s Fitness article also emphasized the study’s limitations, including its small sample size, company sponsorship, and mixed results across broader measures of hangover severity and cognitive impairment. While the findings suggest potential benefits for certain alcohol recovery measures, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive.
For Quantum BioPharma, the coverage represents both an opportunity and a test. The company is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Quantum invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% of Unbuzzd as of March 31, 2026. The agreement also includes royalty payments of 7% of sales from unbuzzd until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The Men’s Fitness coverage may shape how consumers and investors perceive Unbuzzd’s scientific backing. With only a company-sponsored study of 26 participants, the article’s balanced presentation of benefits and limitations could temper expectations while keeping the product in the public conversation. More detailed information about Quantum BioPharma is available through Quantum BioPharma (NASDAQ: QNTM), and the company’s latest news and updates are accessible at https://ibn.fm/QNTM.
Full terms of use and disclaimers applicable to content provided by IBN are available at https://IBN.ai/Disclaimer. The original release can be viewed on www.newmediawire.com.
